The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A mobile app–based program for facilitating advance care planning discussions between patients with advanced cancer and oncologists: A randomized controlled trial (J-SUPPORT 2104).
 
Kyoko Obama
No Relationships to Disclose
 
Maiko Fujimori
No Relationships to Disclose
 
Masako Okamura
No Relationships to Disclose
 
Tatsunori Shimoi
No Relationships to Disclose
 
Shunsuke Oyamada
Honoraria - Chugai Pharma
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; Henlius; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Taro Ueno
Leadership - SUSMED Inc
Stock and Other Ownership Interests - SUSMED Inc
Patents, Royalties, Other Intellectual Property - SUSMED Inc (Inst)
 
Shunsuke Kondo
No Relationships to Disclose
 
Yuki Kojima
No Relationships to Disclose
 
Tempei Miyaji
Honoraria - AYUMI; Pfizer; Welby
Research Funding - 3H Medi Solution (Inst); A2 Healthcare (Inst); AC Medical (Inst); FMD K&L Japan (Inst); intellim (Inst); Japan Media Corporation (Inst); Japan Tobacco Inc (Inst); Medidata Solutions, Inc (Inst); Medrio (Inst); New Age Trading (Inst); Nipro Corporation (Inst); NOBORI Ltd. (Inst); Ono Pharmaceutical (Inst); Welby (Inst)
 
Takayo Sakiyama
No Relationships to Disclose
 
Naomi Sakurai
No Relationships to Disclose
 
Tatsuo Akechi
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Igaku-Shoin; Janssen; Kowa; Kyowa Kirin International; Lundbeck; Meiji Seika Kaisha; Mochida Pharmaceutical Co. Ltd.; MSD; Nipro Corporation; Otsuka; Pfizer; Sumitomo Pharma Oncology; Takeda; Tsumura & Co.; Viatris
Patents, Royalties, Other Intellectual Property - The inventor of the pending patents (2020-135195, 2022-069057) (Institute) and the patents (7313617) (Institute) (Inst)
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Daiichi-Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Takeda (Inst)
 
Masanori Mori
No Relationships to Disclose
 
Taichi Shimazu
No Relationships to Disclose
 
Yoshikuni Nagashio
No Relationships to Disclose
 
Tatsuya Yoshida
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo/UCB Japan; Lilly Japan; MSD Oncology; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai/Roche; Lilly Japan; MSD
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Takuhiro Yamaguchi
Stock and Other Ownership Interests - STATCOM
Consulting or Advisory Role - 3H Clinical Trial; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED.; Eisai; EPS Corporation; Incyte; intellim; Japan Tobacco Inc; Kowa; Merck; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Public Health Research Foundation; Seikagaku; Sonire Therapeutics
Speakers' Bureau - 3H Clinical Trial; Medical Mobile Communications co., Ltd.; Merck
Research Funding - 3H Clinical Trial (Inst); 3H Medi Solution (Inst); A2 Healthcare (Inst); AC Medical (Inst); ClinChoice (Inst); Cordis. (Inst); DAIICHI SANKYO COMPANY, LIMITED. (Inst); Eisai (Inst); Facet Biotech (Inst); Hemp Kitchen (Inst); intellim (Inst); Japan Media Corporation (Inst); Japan Tobacco Inc (Inst); Kyowa Kirin Co., Ltd.; Medidata Solutions, Inc (Inst); Medrio (Inst); NIPRO CORPORATION (Inst); Nobori Ltd. (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Puravida Technologies (Inst); Senju Pharmaceutical (Inst); Solasia Pharma (I); TSUMURA & CO. (Inst); Welby (Inst)
 
Yosuke Uchitomi
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Daiichi-Sankyo; Mitsubishi Tanabe Pharma; Sumitomo Pharma Oncology; Tsumura & Co.; Viatris pharma